SUNDAY, JULY 13, 2014
1:30-5:00 pm – Registration and Partnering Desk Open
3:00-5:00 pm – One-to-One Partnering Program (Coles Ballroom)
7:00 pm – Public Lecture: (Gray Ballroom) – Michael Zigmond, Ph.D. (U. of Pittsburgh) – Returning to our Forebearers: How more exercise can lead to less neurodegeneration
MONDAY, JULY 14, 2014
7:30 am – Registration & Partnering Help Desk Open
7:30-8:15 am – Breakfast & Networking
8:15-8:30 am – Opening Remarks (Grey Ballroom)
8:30-9:45 am – SESSION ONE (Gray Ballroom)
- H. Christian Fibiger, Ph.D. (Medgenesis Therapeutix) – GDNF for the Treatment of Parkinson’s disease
- Patrick Howson, Ph.D. (Junaxo) – Update on the Neurotrophic Factor Modulator JNX1001 (previously known as Cogane): Results from the CONFIDENT-PD study
- Michael Zigmond Ph.D. (U. of Pittsburgh) –Protecting Dopamine Neurons with Neurotrophic Factors
9:45 – 10:05 – Networking Break (Coles Ballroom)
10:05 am – 12:00 – SESSION TWO – Investing in the CNS Sector (Gray Ballroom)
- Genzyme – G. Andre Turenne, Head of Strategy & Business Development (US)
- Servier Canada – Laurent Tillement, D.Pharm., Ph.D., Scientific Advisor (Canada)
- TPBioventures – Tom Blackburn, Ph.D., D.Sc., Founder & CEO (UK)
- NEOMED – Philippe Walker, Ph.D., Chief Scientific Officer (Canada)
12:00-1:00 pm – Lunch – Featuring Dr. James Olds, Krasnow Institute for Advanced Learning (Coles Ballroom)
1:00-2:00 pm – One-to-One Partnering Program (Coles Ballroom)
2:00 – 3:15 pm – SESSION THREE (Gray Ballroom)
- Dale Corbett, Ph.D. (U. of Ottawa) – Neuroregenerative Approaches to Stroke Recovery: BDNF, exercise and stem cell strategies to promote recovery
- Brandi Ormerod, Ph.D. (U. of Florida) Neuroimmune Signaling, Hippocampal Neurogenesis & Cognition Across Lifespan
- Marie-Francoise Chesselet, M.D. Ph.D. (UCLA) – Modeling Non-motor Deficits in Parkinson’s disease: Why and How?
3:15 – 3:35 pm – Networking Break (Coles Ballroom)
3:35 – 4:30 pm – SESSION FOUR (Gray Ballroom)
- Charles K. Meschul, Ph.D.,(Oregon Health & Science University) Genetic Silencing of the Subthalamic Nucleus or TrkB Activation Blocks Dopamine Loss in a Mouse Model of Parkinson’s Disease
- Thérèse Di Paolo, Ph.D. (Laval University) – Neuroprotection & Rescue in the MPTP Mouse Model of Parkinson’s disease: from Estrogens to Lipids
5:45 pm – Bus departs Delta Prince Edward for Seaside Lobster Social
TUESDAY, JULY 15, 2014
7:30 am – Registration & Partnering Help Desk Opens
7:30-8:15 am – Breakfast & Networking
8:15-8:30 am – Opening Remarks (Gray Ballroom)
8:30 – 9:45 am – SESSION FIVE – (Gray Ballroom)
- David Westaway, Ph.D. (U. of Alberta) – Host Protective Response in CNS Prion Diseases: A window on pathogenesis and intervention
- Niclas Brynne, Ph.D. (MentisCura Diagnostics, Iceland) – EEG as a Marker for Alzheimer’s Disease
- Nadine Kabbani, Ph.D. (George Mason University) – Cellular Mechanisms of Synaptic Growth and Regeneration driven by the Alpha 7 Nicotinic Receptor in the Brain
9:45 – 10:05 am – Networking Break (Coles Ballroom)
10:05 am – 12:00 pm – SESSION SIX – Investing in the CNS Sector (Gray Ballroom)
- Eli Lilly Canada – Luc Boulay, Ph.D., Regional MSL Manager (Quebec/Atlantic Canada)
- Libramen Naturals – Michael Rathbone, M.B. Ch.B., Ph.D., FRCPC (Canada)
- Somru Bioscience – Mohammed Moin, Vice President of Business Development (Canada)
- Fundacion MEDINA – Francisca Vicente, Ph.D., Area Head of Screening and Target Validation (Spain)
12:00-1:00 pm – Lunch (Gray Ballroom)
1:00-2:20 pm – One-to-One Partnering Program (Coles Ballroom)
2:20 – 3:10 – SESSION SEVEN (Gray Ballroom)
- Alfred Maelicke, Ph.D. (Galantos Pharma) – Phase 1 Clinical Trial Results of the Cognitive Enhancer, Memogain
- Jackalina Van Kampen, Ph.D. (Neurodyn) – Disease Modifying Effects of Memogain
3:10 – 3:30 pm – Networking Break (Coles Ballroom)
3:30 – 4:45 pm – SESSION EIGHT (Gray Ballroom)
- George Robertson, Ph.D. (Dalhousie U.) – Optimization of Mitochrondrial-based Neurotherapeutics
- Mickael Decressac, Ph.D. (Telethon Institute of Genetics & Medicine, Italy) – Nurr1 in Parkinson’s Disease: From Pathogenesis to Therapeutic Potential
- Christine Vande Velde, Ph.D. (U. of Montreal) – RNA Granules in ALS Pathogenesis
4: 45 pm – Closing Remarks (Gray Ballroom)